The FDA will promote the use of lab-grown human “organoids” and organ-on-a-chip systems that mimic human organs to test drug safety. These experiments can reveal toxic effects that could easily go undetected in animals, providing a more direct window into human responses. The FDA is thus once again concretizing the 3R decision from January 2024.

Since 2018, abc biopply's proprietary 3D CoSeedis humanized multi-organoid in chip models™ and its preclinical services, are reshaping conventional preclinical research. By crafting miniature patient organs in tissue replicas, the company achieves self-organization of physiological microenvironments with unparalleled precision in predicting treatment responses. Documented in over 20 recognized scientific publications and protected by multiple intellectual property rights, abc biopply's technology is a game-changer, positioning the company as an industry leader.

At abc biopply, we understand how crucial it is to receive accurate and reliable reports to meet regulatory deadlines and support the success of your projects. With our standardaized, ready-to-use packages like the Rapid Drug Efficacy Check our team will deliver in the shortest time possible a most accurate prediction of clinically relevant drug efficacy and dosages during hit validation, lead optimization and the preclinical test phase. It profits from the unique features of the 3D CoSeedis™ in chip technology forming physiologically relevant micro-tissues in statistically significant quantities.

Contact us for more details!